Boston Scientific Corporation reported robust Q2 2024 financial results, with net sales of $4.120 billion, up 14.5% on a reported basis and 14.7% organically year-over-year. GAAP net income attributable to common stockholders was $324 million or $0.22 per share, while adjusted EPS reached $0.62, surpassing guidance.The company achieved significant growth across all segments and regions, with Cardiovascular sales up 17.8% and MedSurg sales increasing 9.0%. Notable developments include NMPA approval in China for the FARAPULSE Pulsed Field Ablation System and positive clinical data presentations for various products.Boston Scientific raised its full-year 2024 guidance, now projecting net sales growth of 13.5% to 14.5% on a reported basis and 13% to 14% organically. The company estimates full-year adjusted EPS to be in the range of $2.38 to $2.42, reflecting confidence in its continued strong performance and strategic initiatives.

Boston Scientific Corporation reported robust Q2 2024 financial results, with net sales of $4.120 billion, up 14.5% on a reported basis and 14.7% organically year-over-year. GAAP net income attributable to common stockholders was $324 million or $0.22 per share, while adjusted EPS reached $0.62, surpassing guidance.The company achieved significant growth across all segments and regions, with Cardiovascular sales up 17.8% and MedSurg sales increasing 9.0%. Notable developments include NMPA approval in China for the FARAPULSE Pulsed Field Ablation System and positive clinical data presentations for various products.Boston Scientific raised its full-year 2024 guidance, now projecting net sales growth of 13.5% to 14.5% on a reported basis and 13% to 14% organically. The company estimates full-year adjusted EPS to be in the range of $2.38 to $2.42, reflecting confidence in its continued strong performance and strategic initiatives.